Merck to acquire EyeBio in potential $3B deal : vimarsana.co

The privately held ophthalmology-focused biotechnology company focuses on the treatment of vision loss associated with retinal vascular leakage.

Related Keywords

David Guyer , Kate Bingham , Tony Adamis , Merck Research Laboratories , Sv Health Investors , Centerview Partners , Meagher Flom , Gibson , Rahway Headquartered Merck , Hart Scott Rodino Antitrust Improvements Act ,